Octagon Capital Advisors LP Invests $17.26 Million in Disc Medicine, Inc. $IRON

Octagon Capital Advisors LP bought a new stake in Disc Medicine, Inc. (NASDAQ:IRON) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 270,000 shares of the company’s stock, valued at approximately $17,264,000. Disc Medicine comprises approximately 1.9% of Octagon Capital Advisors LP’s portfolio, making the stock its 18th largest position.

Several other institutional investors also recently bought and sold shares of the stock. SG Americas Securities LLC increased its stake in Disc Medicine by 161.9% in the 4th quarter. SG Americas Securities LLC now owns 21,122 shares of the company’s stock worth $1,677,000 after purchasing an additional 13,058 shares during the period. NEXTBio Capital Management LP purchased a new stake in shares of Disc Medicine during the fourth quarter valued at approximately $3,397,000. Eagle Health Investments LP purchased a new stake in shares of Disc Medicine during the fourth quarter valued at approximately $2,152,000. DNB Asset Management AS grew its holdings in shares of Disc Medicine by 1,425.8% in the fourth quarter. DNB Asset Management AS now owns 84,255 shares of the company’s stock worth $6,691,000 after purchasing an additional 78,733 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Disc Medicine by 22.1% in the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after purchasing an additional 319,621 shares during the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Disc Medicine Price Performance

IRON opened at $74.12 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.00 and a current ratio of 24.00. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The stock has a market capitalization of $2.83 billion, a PE ratio of -11.20 and a beta of 0.97. The stock’s 50 day moving average price is $71.79 and its 200-day moving average price is $69.73.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). On average, equities research analysts predict that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on IRON. Morgan Stanley upped their price target on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, June 15th. Wedbush reissued an “outperform” rating and issued a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $104.44.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 18,612 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $3,758,677.56. This represents a 25.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rahul Khara sold 7,500 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00. Following the completion of the transaction, the insider owned 52,173 shares of the company’s stock, valued at $3,663,588.06. This trade represents a 12.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 105,712 shares of company stock valued at $7,597,536. 3.76% of the stock is currently owned by company insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.